Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval.The treatment for hemophilia A could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for a less common type of the bleeding disorder called hemophilia B. Pfizer is co-developing the therapy with Sangamo Therapeutics, whose shares rose more than 60% on Wednesday following the ...